First Tracks Biotherapeutics (TRAX) Stock Price, News & Analysis

Company Overview

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.

Key Stats

• Today's Range: $40.72 to $44.79
• 50-Day Range: $16.03 to $47.92
• 52-Week Range: $14.72 to $49.91
• Volume: 527,865 shs
• Average Volume: 732,379 shs
• Market Capitalization: $1.54 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $63.00
• Consensus Rating: Moderate Buy

First Tracks Biotherapeutics Stock Analysis - MarketRank™

First Tracks Biotherapeutics scored higher than 71% of companies evaluated by MarketBeat, and ranked 197th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

First Tracks Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on no strong buy ratings, 9 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

First Tracks Biotherapeutics has a consensus price target of $63.00, representing about 46.1% upside from its current price of $43.11.

Amount of Analyst Coverage

First Tracks Biotherapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for First Tracks Biotherapeutics are expected to grow in the coming year, from ($4.31) to ($3.84) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of First Tracks Biotherapeutics is -23.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of First Tracks Biotherapeutics is -23.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

First Tracks Biotherapeutics has a P/B Ratio of 9.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.34% of the float of First Tracks Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

First Tracks Biotherapeutics has a short interest ratio ("days to cover") of 4.63.

Change versus previous month

Short interest in First Tracks Biotherapeutics has recently decreased by 17.07%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

First Tracks Biotherapeutics does not currently pay a dividend.

Dividend Growth

First Tracks Biotherapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: -0.03

News Sentiment

First Tracks Biotherapeutics has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for First Tracks Biotherapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 3 people have searched for TRAX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

3 people have added First Tracks Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, First Tracks Biotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Institutions

First Tracks Biotherapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 8/23/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:TRAX
• CIK: 2091349
• Web: www.firsttracksbio.com
• Phone: 858-362-6295
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for First Tracks Biotherapeutics: $63.00
• High Price Target: $95.00
• Low Price Target: $31.00
• Potential Upside/Downside: +46.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.73
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.28
• Quick Ratio: 14.28

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.72 per share
• Price / Book: 9.13

Miscellaneous

• Outstanding Shares: 35,730,000
• Free Float: N/A
• Market Cap: $1.54 billion
• Optionable: N/A
• Beta: N/A